期刊文献+

替罗非班在急性ST段抬高型心肌梗死患者PCI术后的疗效及安全性分析 被引量:2

下载PDF
导出
摘要 目的:探讨替罗非班治疗急性ST段抬高型心肌梗死患者经皮冠状动脉介入术(PCI)术后的疗效及安全性。方法:选取我院2013年1月—2014年6月确诊为急性ST段抬高型心肌梗死并急诊PCI术治疗的患者90例,随机分为观察组与对照组,对照组采用阿司匹林与氯吡格雷治疗,观察组采用替罗非班治疗,对比分析两组疗效。结果:观察组术后1个月左心功能指标及生化指标明显优于对照组(P<0.05),观察组血管TIMI血流分级≤2级的获得率明显低于对照组(P<0.05),观察组血管TIMI血流分级3级获得率明显高于对照组(P<0.05),观察组心血管事件(MACE)发生率明显低于对照组(P<0.05),两组出血发生率差异无统计学意义(P>0.05)。结论:替罗非班在急性ST段抬高型心肌梗死患者PCI术后具有明显疗效,且安全性高。
作者 伍远雄
出处 《临床医药实践》 2015年第10期745-747,共3页 Proceeding of Clinical Medicine
  • 相关文献

参考文献7

二级参考文献63

  • 1龚平,王朝晖,杜林林,刘小楣,罗丰,胡家顺.替罗非班在家兔血栓模型中对血小板聚集的影响[J].中国药学杂志,2006,41(8):593-596. 被引量:8
  • 2Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量:43
  • 3Martinez-Rios MA,Rosas M,Gonzalez H,et al.Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction[J].Am J Cardiol,2004,93(3):280-287.
  • 4Kasrati A,Mehilli J,Neumann FJ,et al.Abciximab in patients with aculte coronary syndromes undergoing percutneous coronary intervention after clopidogrel pretreatment:the ISAR-REACT2 Randomized Trial[J].JAMA,2006,295:1531-1538.
  • 5Lavi S,Gruberg L,Kapeliovich M.The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients[J].J Invasive Cardiol,2005,17(6):296-299.
  • 6Kearney D,Byrne A,Crean P,et al.Optimal suppression of thromboxane A2 for formation by aspirin during percutaneous transluminal coronary angioplasty:noadditional effect of a selective cyclooxygenase-2 inhibitor[J].J Am Coll Cardiol,2004,43(4):532-535.
  • 7Saint Jacques H,Harrington AR.Glucoprotein receptor inhibitors in the management of acute coronary syndroms[J].Curr Cardiol Rep,2002,4(4):301-312.
  • 8Boersma E, Harrington RA, Molitemo D J, et al. Platelet glycoprotein Ⅱ b/Ⅲ a inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet, 2002, 359: 189-198.
  • 9Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneons coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation, 2002,106: 1470-1476.
  • 10Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the Gold ( AU-Assessing Ultegra) multicenter study. Circulation. 2001, 103: 2572-2578.

共引文献2056

同被引文献15

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部